Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

NCT04023071 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT04023071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04023071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
October 4, 2019
Completion date
October 23, 2023
Enrollment
72 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, b-cell lymphoma